Navigation Links
Discovery could improve hepatitis C treatment
Date:9/23/2009

Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments.

Dr Melanie Bahlo and Dr Max Moldovan from the institute's Bioinformatics division worked with researchers from the University of Sydney and elsewhere to analyse the genomes of more than 800 people, including more than 300 Australians, who were receiving treatment for chronic hepatitis C infection.

Their genome-wide association study of people receiving hepatitis C treatment revealed that genetic variants near the interferon gene IL28B were associated with people's response to treatment.

Three per cent of the world's people are infected with hepatitis C and few are able to clear the virus without treatment.

The standard treatment is a combination of pegylated interferon-alpha and ribavirin (PEG-IFN-alpha/RBV). However this treatment is expensive ($20,000 per person in Australia), can have serious adverse effects and is unsuccessful in 50-60 per cent of cases.

At present it is not possible to identify the 40-50 per cent of people who will respond well to treatment.

To address this problem, Dr Moldovan and Dr Bahlo are building and evaluating statistical models that incorporate genetic variants, in combination with clinical and baseline factors, to best predict treatment outcome.

Through this approach the research team found that people having a specific genetic profile at a genetic variant called rs8099917 showed the strongest virological response when undergoing treatment.

The research results were published online last week in the international journal Nature Genetics. Two other research papers validating the same finding have been published in the past month.

Dr Bahlo said with the knowledge of the gene variants it would be possible to develop a diagnostic test, based on a person's genetic profile, to identify those who are likely to respond to treatment with PEG-IFN-alpha/RBV.

Further, the location of the newly-discovered genetic variant opens the way for development of a more effective hepatitis C treatment, which is likely to result in fewer adverse effects than PEG-IFN-alpha/RBV.

Finding effective treatments is essential as many people infected with hepatitis C become chronic carriers of the disease and may develop liver cirrhosis or liver cancer.


'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Related medicine news :

1. Discoverys Edge Fall Issue -- http://discoverysedge.mayo.edu/
2. 3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st
3. Discovery May Pave Way to Better Diabetes Care
4. Alzheimers Drug Discovery Foundation Funds Abiant, Inc. to Develop a Positron Emission Tomography (PET) Imaging Diagnostic for Alzheimers Disease
5. Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity
6. Genetic Discovery May Improve Hepatitis C Treatment
7. New discovery brings hope to treatment of lymphatic diseases
8. Immune System Gene Discovery Sheds Light on Staph Infections
9. Cell Discovery May Bring Science Closer to Diabetes Cure
10. The Psychology of Frailty: An Identity Crisis Among the Elderly - Alzheimers Drug Discovery Foundations Dr. Howard Fillit to Co-Chair Symposium
11. Toronto researchers discovery points to a new treatment avenue for acute myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Discovery could improve hepatitis C treatment
(Date:2/17/2017)... ... February 17, 2017 , ... ... executives and focusing on all facets of clinical trial planning and management. Pharmica ... patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were able ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses ... Foundation Summit from February 21 - 23 in Beaver Creek, CO. It was announced ... the Summit’s second year in Beaver Creek, hosting over 60 faculty members and addressing ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer survivors, ... final treatments. Physician researchers at The Marcus Institute of Integrative Health at ... efficacy in reducing symptoms of traumatic stress in cancer patients and published ...
(Date:2/16/2017)... ... February 16, 2017 , ... Doctors on Liens is ... to their network through his work at BKP Chiropractic in Lancaster . ... medical degree from Canada’s prestigious International Baccalaureate Program, Dr. Raj went on to ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... ... with the best products in treatment for hair loss, announced today that the ... for over-the-counter (OTC) treatment of hair loss, as well as its clinical-use standing ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017   FormFast , the ... a new partnership with Engage , one of ... States . FormFast will serve as the forms ... implementations with MEDITECH .  FormFast ... functionality to complement and enhance the electronic health record. ...
(Date:2/16/2017)... Absorption Systems, a global leader in nonclinical ... to announce that its Chief Operating Officer, Sid ... of the 2017 Executive Management Award. The award is ... executives for their creative management vision, leadership philosophy, innovative ... celebration is on March 8, 2017 at the Ballroom ...
(Date:2/16/2017)... 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... today announced that executive management will participate in the ... February 22-23, 2017. Adrian Adams , Chief Executive ... 1:35 p.m. local time on Wednesday, February 22, 2017. ... the event may be accessed from the Investors section ...
Breaking Medicine Technology: